Bionomics Ltd (BNOEF) Starts Presentation at 29th Annual ROTH Conference
Bionomics (OTC: BNOEF) is a global, clinical stage biopharmaceutical company leveraging its proprietary platform technologies to discover and develop a deep pipeline of novel drug candidates. The company focuses on the treatment of serious central nervous system disorders and on the treatment of cancer. Bionomics' lead drug candidate BNC210, currently in phase 2 for the treatment of generalized anxiety disorder and for post-traumatic stress disorder, is a novel, proprietary negative allosteric modulator of the alpha-7 (α7) nicotinic acetylcholine receptor. The company is also developing BNC101, its lead humanized monoclonal antibody targeting a key receptor on cancer stem cells that is…







